Nature Communications (Jul 2021)
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade
- Octavio A. Romero,
- Andrea Vilarrubi,
- Juan J. Alburquerque-Bejar,
- Antonio Gomez,
- Alvaro Andrades,
- Deborah Trastulli,
- Eva Pros,
- Fernando Setien,
- Sara Verdura,
- Lourdes Farré,
- Juan F. Martín-Tejera,
- Paula Llabata,
- Ana Oaknin,
- Maria Saigi,
- Josep M. Piulats,
- Xavier Matias-Guiu,
- Pedro P. Medina,
- August Vidal,
- Alberto Villanueva,
- Montse Sanchez-Cespedes
Affiliations
- Octavio A. Romero
- Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona
- Andrea Vilarrubi
- Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona
- Juan J. Alburquerque-Bejar
- Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona
- Antonio Gomez
- Rheumatology Research Group, Vall d’Hebron Research Institute
- Alvaro Andrades
- Department of Biochemistry and Molecular Biology I. Faculty of Sciences, University of Granada
- Deborah Trastulli
- Genes and Cancer Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute-IDIBELL Barcelona
- Eva Pros
- Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona
- Fernando Setien
- Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona
- Sara Verdura
- Genes and Cancer Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute-IDIBELL Barcelona
- Lourdes Farré
- Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet del Llobregat
- Juan F. Martín-Tejera
- Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet del Llobregat
- Paula Llabata
- Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona
- Ana Oaknin
- Department of Medical Oncology, Vall d’Hebrón Hospital
- Maria Saigi
- Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona
- Josep M. Piulats
- Department of Medical Oncology, Catalan Institute of Oncology (ICO)
- Xavier Matias-Guiu
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, CIBERONC, L’Hospitalet del Llobregat
- Pedro P. Medina
- Department of Biochemistry and Molecular Biology I. Faculty of Sciences, University of Granada
- August Vidal
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, CIBERONC, L’Hospitalet del Llobregat
- Alberto Villanueva
- Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet del Llobregat
- Montse Sanchez-Cespedes
- Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona
- DOI
- https://doi.org/10.1038/s41467-021-24618-3
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
SMARCA4 is commonly inactivated in lung and ovarian cancers. Here the authors show that SMARCA4-deficient tumours have significantly reduced levels of the histone demethylases KDM6s and a strong dependency on these demethylases for tumour growth, so that they are vulnerable to KDM6s inhibition.
